AIM: To investigate that inflammatory markers can predict accurately the prognosis of hepatocelluar carcinoma (HCC) patients in living-donor liver transplantation (LDLT). METHODS: From October 2000 to November 2011, 224 patients who underwent living donor liver transplantation for HCC at our institution were enrolled in this study. We analyzed disease-free survival (DFS) and overall survival (OS) after LT in patients with HCC and designed a new score model using pretransplant neutrophil-lymphocyte ratio (NLR) and C-reactive protein (CRP). RESULTS: The DFS and OS in patients with an NLR level ≥ 6.0 or CRP level ≥ 1.0 were significantly worse than those of patients with an NLR level < 6.0 or CRP level < 1.0 (P = 0.049, P = 0.003 for NLR and P = 0.010, P < 0.001 for CRP, respectively). Using a new score model using the pretransplant NLR and CRP, we can differentiate HCC patients beyond the Milan criteria with a good prognosis from those with a poor prognosis. CONCLUSION: Combined with the Milan criteria, new score model using NLR and CRP represent new selection criteria for LDLT candidates with HCC, especially beyond the Milan criteria.
AIM: To investigate that inflammatory markers can predict accurately the prognosis of hepatocelluar carcinoma (HCC) patients in living-donor liver transplantation (LDLT). METHODS: From October 2000 to November 2011, 224 patients who underwent living donor liver transplantation for HCC at our institution were enrolled in this study. We analyzed disease-free survival (DFS) and overall survival (OS) after LT in patients with HCC and designed a new score model using pretransplant neutrophil-lymphocyte ratio (NLR) and C-reactive protein (CRP). RESULTS: The DFS and OS in patients with an NLR level ≥ 6.0 or CRP level ≥ 1.0 were significantly worse than those of patients with an NLR level < 6.0 or CRP level < 1.0 (P = 0.049, P = 0.003 for NLR and P = 0.010, P < 0.001 for CRP, respectively). Using a new score model using the pretransplant NLR and CRP, we can differentiate HCC patients beyond the Milan criteria with a good prognosis from those with a poor prognosis. CONCLUSION: Combined with the Milan criteria, new score model using NLR and CRP represent new selection criteria for LDLT candidates with HCC, especially beyond the Milan criteria.
Authors: Francis Y Yao; Linda Ferrell; Nathan M Bass; Peter Bacchetti; Nancy L Ascher; John P Roberts Journal: Liver Transpl Date: 2002-09 Impact factor: 5.799
Authors: Matteo Cescon; Valentina Rosa Bertuzzo; Giorgio Ercolani; Matteo Ravaioli; Federica Odaldi; Antonio Daniele Pinna Journal: World J Gastroenterol Date: 2013-12-28 Impact factor: 5.742
Authors: P Moreno; E Jaurrieta; J Figueras; C Benasco; A Rafecas; J Fabregat; J Torras; T Casanovas; L Casais Journal: Transplant Proc Date: 1995-08 Impact factor: 1.066
Authors: F Y Yao; L Ferrell; N M Bass; J J Watson; P Bacchetti; A Venook; N L Ascher; J P Roberts Journal: Hepatology Date: 2001-06 Impact factor: 17.425
Authors: J Figueras; L Ibañez; E Ramos; E Jaurrieta; J Ortiz-de-Urbina; F Pardo; J Mir; C Loinaz; L Herrera; P López-Cillero; J Santoyo Journal: Liver Transpl Date: 2001-10 Impact factor: 5.799
Authors: V Mazzaferro; E Regalia; R Doci; S Andreola; A Pulvirenti; F Bozzetti; F Montalto; M Ammatuna; A Morabito; L Gennari Journal: N Engl J Med Date: 1996-03-14 Impact factor: 176.079
Authors: Arno Kornberg; Martina Schernhammer; Jennifer Kornberg; Helmut Friess; Katharina Thrum Journal: Dig Dis Sci Date: 2018-09-27 Impact factor: 3.199
Authors: Randy C Bowen; Nancy Ann B Little; Joshua R Harmer; Junjie Ma; Luke G Mirabelli; Kyle D Roller; Andrew Mackay Breivik; Emily Signor; Alec B Miller; Hung T Khong Journal: Oncotarget Date: 2017-05-09
Authors: Tobias Meischl; Susanne Rasoul-Rockenschaub; Georg Györi; Wolfgang Sieghart; Thomas Reiberger; Michael Trauner; Thomas Soliman; Gabriela Berlakovich; Matthias Pinter Journal: PLoS One Date: 2019-05-29 Impact factor: 3.240